Loading stock…

Nuvation Bio Inc. (NUVB) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Nuvation Bio Inc.

NUVBMarket cap $1.74BPrice $5.0

Country🇺🇸United States

SectorHealthcare

IndustryPharmaceuticals

Develops targeted cancer therapies designed to fight tumors while sparing healthy tissue, tackling treatment-resistant mutations other drugmakers avoid. This clinical-stage biotech bets everything on precision oncology, with no approved products yet generating revenue.

In Bastion Portfolios?

52W Return+45%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)na–

Revenue Forecast

Rev CAGR (1y)+215%10

Rev CAGR (3y)+89%10

Rev CAGR (5y)+59%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+30%5

Quality

Margins

EBIT Margin-81%1

Net Income Margin-88%1

Free Cash Flow Margin-71%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-48%1

ROA-22%1

Earnings Stabilityna–

GEAR+VERY WEAK7

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)5401

P/BV6.82

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-7.0%1

Dividend Yieldna–

Momentum

Short term

1 month return-24%1

3 month return-19%2

YTD return-45%1

Mid term

Price vs 52wHigh51%1

1 year return+32%8

Long term

3 year return+309%10

5 year return-46%2

Risk Shield

Price Risk

Beta1.61

Volatility81%1

Free Cash Flow

Free Cash Flow Margin-71%1

Free Cash Flow Yield-7.0%1

Quality

ROCE-22%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

NUVBNuvation Bio

Revenue FY25$63M

GROWTH RATING↗

STRONG79 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Y+215%10

Revenue, next 3Y, CAGR+89%10

Revenue, next 5Y, CAGR+59%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28E0%5

GROWTH ASSESSMENT

STRENGTHS

It out-grows 79% of companies worldwide.

Revenue is set to grow 89%/yr over the next 3 years, ahead of most of the market.10/10

Revenue held flat over the last 3 years and is set to grow 89%/yr from here.

The runway holds up: revenue is set to grow 59%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK21 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-24%1

3-month return-19%2

YTD return-45%1

MID & LONG-TERM▾SCORE

% of 52-week high51%1

1-year return+32%8

3-year return+309%10

5-year return-46%2

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Average long-term results. Multi-year returns are middling (+309% over three years and -46% over five), roughly average for the market.

It's up 32% over the past year, but 49% below its 52-week high. That is right in line with the market.

WEAKNESSES

The stock is underperforming over the past month (-24%), over three months (-19%) and so far this year (-45%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the stock is underperforming over the past month, over three months and so far this year.

04Value

Are you paying a fair price for it?

Stop guessing on Nuvation Bio Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

NUVBNuvation Bio

Revenue FY25$63M

GROWTH RATING↗

STRONG79 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Y+215%10

Revenue, next 3Y, CAGR+89%10

Revenue, next 5Y, CAGR+59%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28E0%5

GROWTH ASSESSMENT

STRENGTHS

It out-grows 79% of companies worldwide.

Revenue is set to grow 89%/yr over the next 3 years, ahead of most of the market.10/10

Revenue held flat over the last 3 years and is set to grow 89%/yr from here.

The runway holds up: revenue is set to grow 59%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK21 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-24%1

3-month return-19%2

YTD return-45%1

MID & LONG-TERM▾SCORE

% of 52-week high51%1

1-year return+32%8

3-year return+309%10

5-year return-46%2

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Average long-term results. Multi-year returns are middling (+309% over three years and -46% over five), roughly average for the market.

It's up 32% over the past year, but 49% below its 52-week high. That is right in line with the market.

WEAKNESSES

The stock is underperforming over the past month (-24%), over three months (-19%) and so far this year (-45%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Nuvation Bio Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community